| Oct 29 |
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
|
| Oct 25 |
Bioventus files for $200M mixed securities shelf
|
| Oct 22 |
Bioventus Surges 73% in Three Months: Time to Buy the Stock?
|
| Oct 18 |
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?
|
| Oct 15 |
Solventum Stock Earns 81 RS Rating
|
| Oct 9 |
Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
| Oct 1 |
Bioventus announces divestiture of its Advanced Rehabilitation business to Accelmed Partners
|
| Oct 1 |
Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
|
| Sep 27 |
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
|
| Sep 26 |
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
|
